Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.
暂无分享,去创建一个
C. Mussi | F. Gherlinzoni | S. Bonvalot | A. Cesne | A. D. Dei Tos | A. Le Cesne | P. Casali | A. Marrari | A. Gronchi | C. Le Péchoux | N. Penel | F. Gouin | G. Grignani | J. Blay | E. Stoeckle | F. Duffaud | P. Méeus | C. Péchoux | F. Gouin | M. Fiore | F. Gherlinzoni | C. Colombo | P. Meeus | A. Tos | C. Mussi | Nicolas Penel
[1] M. Bertagnolli,et al. Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk , 2014, Annals of surgery.
[2] S. Bonvalot,et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence , 2013, Cancer.
[3] S. Gwyther,et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] S. Bonvalot,et al. Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought , 2013, Annals of Surgical Oncology.
[5] David W. Henry,et al. Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.
[6] P. Rose,et al. Desmoid: The Role of Local Therapy In an Era of Systemic Options , 2013, Current Treatment Options in Oncology.
[7] P. Terrier,et al. The treatment of desmoid tumors: a stepwise clinical approach. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] J. Blay,et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] M. Bertagnolli,et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. , 2012, Cancer research.
[10] J. Blay,et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Casali,et al. Activity of toremifene in sporadic desmoid-type fibromatosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Blay,et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] C. Antonescu,et al. Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.
[14] Dafydd G. Thomas,et al. Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial , 2010, Clinical Cancer Research.
[15] C. Antonescu,et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) , 2010, Cancer.
[16] Patrick T. Liu,et al. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors , 2010, Skeletal Radiology.
[17] Robin L. Jones,et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.
[18] P. Terrier,et al. Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient , 2009, Annals of Surgical Oncology.
[19] A. Gronchi,et al. Desmoid-type fibromatosis: what works best? , 2009, European journal of cancer.
[20] L. Mariani,et al. Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.
[21] F. van Coevorden,et al. Desmoid tumors: need for an individualized approach , 2009, Expert review of anticancer therapy.
[22] A. Lazar,et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.
[23] M. Ballo,et al. Long-term outcomes for desmoid tumors treated with radiation therapy. , 2008, International journal of radiation oncology, biology, physics.
[24] J. Blay,et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[25] A. Lazar,et al. Desmoid tumor: a disease opportune for molecular insights. , 2008, Histology and histopathology.
[26] S. Tejpar,et al. TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. , 2007, Experimental cell research.
[27] M. Ballo,et al. Optimizing treatment of desmoid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Skapek,et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Fletcher,et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Montag,et al. Estrogen receptor‐β expression in extraabdominal fibromatoses , 2006 .
[31] R. Benjamin,et al. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Mariani,et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Thomas,et al. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles , 2004, The British journal of surgery.
[34] L. Mariani,et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] G. Aravantinos,et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Hans Clevers,et al. β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[37] Axel Hoos,et al. Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas , 2002, Annals of surgery.
[38] P. Casali,et al. Low‐dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis , 2001, Cancer.
[39] F. Bertoni,et al. Extraabdominal Desmoid Tumor: A Study of 83 Cases , 2000, Clinical orthopaedics and related research.
[40] Charles R. Thomas,et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors , 2000, Cancer.
[41] H. Kogelnik. [Surgery versus radiotherapy for patients with aggressive fibromatosis or desmoid tumors. A comparative review of 22 articles]. , 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[42] D. Leung,et al. The enigma of desmoid tumors. , 1999, Annals of surgery.
[43] A. Weiss,et al. Therapy of desmoid tumors and fibromatosis using vinorelbine. , 1999, American journal of clinical oncology.
[44] M. Ballo,et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Gebhardt,et al. Individualizing management of aggressive fibromatoses. , 1998, International journal of radiation oncology, biology, physics.
[46] B. Alman,et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). , 1997, The American journal of pathology.
[47] A. Botha,et al. Desmoids in familial adenomatous polyposis , 1997, The British journal of surgery.
[48] N. Pereyo,et al. Extraabdominal desmoid tumor. , 1996, Journal of the American Academy of Dermatology.
[49] H. Steenfos,et al. Growth factors and wound healing. , 1994, Scandinavian journal of plastic and reconstructive surgery and hand surgery.
[50] G. Schultz,et al. Growth factors and wound healing: biochemical properties of growth factors and their receptors. , 1993, American journal of surgery.
[51] J. Reitamo,et al. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. , 1986, American journal of surgery.
[52] G Markhede,et al. Extra-abdominal desmoid tumors. , 1986, Acta orthopaedica Scandinavica.